PARLIAMENTARY WRITTEN QUESTION
Ivacaftor/tezacaftor/elexacaftor (15 January 2024)

Departmental officials regularly discuss a range of issues with colleagues in the National Institute for Health and Care Excellence (NICE), including in relation to the development of guidance on individual products. The Department has had no recent discussions with Vertex.

NICE is an independent body, and its recommendations are developed in accordance with its published methods and processes. NICE is currently developing guidance for the National Health Service on whether Kaftrio, and other cystic fibrosis medicines, represents a clinically and cost effective use of NHS resources and recently consulted on its draft recommendations. Kaftrio is currently available as a treatment option for eligible NHS patients under the terms of an interim access agreement, which was originally reached in 2019.